BioGeometry Secures Hundreds of Millions in Strategic Financing to Pioneer Bio AI World Models
Recently, BioGeometry announced the completion of a new round of strategic financing, raising hundreds of millions of RMB. This round
Recently, BioGeometry announced the completion of a new round of strategic financing, raising hundreds of millions of RMB. This round
For the first time, GeoFlow V3 unifies generation, evaluation and in silico evolution of antibody binders, significantly improving their bind rates to 15.5%, 50x higher than SOTA methods in 2024.
BioGeometry has successfully completed a protein engineering project for a key IVD reagent enzyme, delivering results to Nanjing Novozan Biotechnology Co., Ltd.
, BioGeometry and Nanning Harworld Biology held a strategic cooperation signing ceremony for “AI-Driven Synthetic Biology to Accelerate Cell Factory Development.”
BioGeometry was honored “Top 10 Biomanufacturing Potential Unicorns” and “Top 10 Biomanufacturing Platform Services”
Releasing GeoFlow V2, the world’s first unified atomic foundation model for protein design.
BioGeometry, in collaboration with Jianwei Zhu’s team from Shanghai Jiao Tong University’s School of Pharmacy, achieved a remarkable increase in the neutralizing activity of the 8G3 antibody against the latest JN.1 virus variant, boosting it by 1000-1500 times in a short period.
BioGeometry’s generative AI model, GeoFlow, redesigns the hydrophobic regions of transmembrane proteins to be soluble in water while retaining their structure and function.
BioGeometry was honored with the “Computing Power Star” award for its breakthrough in denovo protein design using generative AI and geometric deep learning.
This strategic partnership will leverage the strengths of both companies to advance innovative vaccine development and production, creating cutting-edge vaccines in China and contributing to global health.